P6 - Poster Session 6
Event Time: | Friday May 10, 2019 11:30 am to 1:00 pm |
Topic(s): | General Neurology |
Director(s): | |
Description: | |
Completion Message: | |
CME Credits: | 0 |
Core Competencies: |
Start/End Time | Title | Faculty |
---|---|---|
Currently there are no events in the timeline. |
Speaker | Disclosure |
---|
Start Time | Pub. | Title | Presenter |
---|---|---|---|
000 |
Disclosure:
|
||
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
001 | 18F-AV-1451 Tau Tracer Uptake Correlates with Medial Temporal Lobe Subregional Atrophy in Amyloid Negative Individuals |
Disclosure: Dr. Das has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Rancho Biosciences.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
001 | Imaging analysis differentiates vascular versus inflammatory myelopathies in children |
Disclosure: Dr. Garcia-Dominguez has nothing to disclose.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
002 | Bi-directional Analysis of Tau Propagation between Braak Stages along Functional Connectivity Pathways |
Disclosure: Dr. Seemiller has nothing to disclose.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
002 | Contralateral hippocampal atrophy after temporal lobe surgery: volumetric analysis of preoperative and long-term postoperative MRI |
Disclosure: Dr. Silva has nothing to disclose.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
003 | Brain Glucose metablism in Lewy Body in Dementia: implication for diagnostic criteria |
Disclosure: Dr. CAMINITI has nothing to disclose.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
003 | Cortical atrophyin First-Degree Asymptomatic Relatives of non-familial-TLE Patients |
Disclosure: Dr. Katsurayama has nothing to disclose.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
004 | Diffusion Tensor Imaging in pre-dementia risk states: white matter atrophy findings in Mild Behavioral Impairment |
Disclosure: Dr. Gill has nothing to disclose.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
004 | EEG Source Imaging from Standard Long-term Video EEG Recording in Patients with Medically-refractory Focal Epilepsy |
Disclosure: Dr. Cox has nothing to disclose.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
005 | Novel method utilizing Arterial Spin Labeling single acquisition 3D Echo Planar Imaging for determining CNS Glymphatic Clearance |
Disclosure: Dr. Joseph has nothing to disclose.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
006 | Regionally Specific Variation in Brain Structure in Behavioral Variant Frontotemporal Dementia Compared to Alzheimer’s Dementia |
Disclosure: Dr. Meysami has nothing to disclose.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
006 | Headache, visual loss, and encephalopathy associated with intravenous ozone administration |
Disclosure: Dr. Tong has nothing to disclose.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
007 | Sildenafil Alters Hippocampal Fractional Amplitude of Low Frequency Fluctuations (fALFF) in Patients with Alzheimer’s Disease |
Disclosure: Dr. Samudra has nothing to disclose.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
008 | WMH Progression but not Regression is Associated with a Higher CSF tau/Aß and Temporal Amyloid Concentration in The Amyloid PET Scan |
Disclosure: Dr. Al-Janabi has nothing to disclose.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
008 | White and Gray Matter Brain Volumes in Early-Onset Alexander Disease |
Disclosure: Dr. Sollee has nothing to disclose.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
009 | Distribution of Hippocampal Tau Pathology in Amnestic and Non-Amnestic Forms of Alzheimer’s Disease |
Disclosure: Dr. Miller has nothing to disclose.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
009 | 3-D Brain Tumor Modeling for Improved Patient Health Literacy and Trainee Education |
Disclosure: Dr. Gatson has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novocure (Optune).
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
010 | Machine Learning of Quantified Volumetric MR Imaging for Diagnostic Delineation of Alzheimer’s Dementia and Mild Cognitive Impairment in the Alzheimer's Disease Neuroimaging Initiative |
Disclosure: Dr. Raji has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Brain reader.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
010 | Glioblastoma multiforme that present with radiographic dural tails. Questioning the prognosis paradigm with case-based evidence of greater than average length of survival |
Disclosure: Dr. Michaelson has nothing to disclose.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
011 | Machine Learning of Quantified Volumetric MR Imaging for Diagnostic Delineation of Alzheimer’s Dementia and Mild Cognitive Impairment in the Alzheimer's Disease Neuroimaging Initiative |
Disclosure: Dr. Raji has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Brain reader.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
011 | iPROMPT: Integrated Predictive Radiographic biOMarkers of Progressed high grade astrocytic Tumors |
Disclosure: Dr. Gatson has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novocure (Optune).
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
012 | Planning a Glioma Partial Resection with DTI Tractography and Virtual Reality |
Disclosure: Dr. Sanicola has nothing to disclose.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
013 | Amyloid PET in multiple sclerosis predicts cognitive decline at 18 months |
Disclosure: Dr. Matias-Guiu has nothing to disclose.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
013 | Development of the Summer NeuroImaging Research Program (SNIRP) for Undergraduates: Novel Research to Engage Students and Enhance the Academic Mission |
Disclosure: Dr. Absher has nothing to disclose.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
014 | Cerebellar Volume Loss in Radiologically Isolated Syndrome |
Disclosure: Dr. George has nothing to disclose.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
016 | Long-Term Monitoring Of Brain Volume Loss In Multiple Sclerosis |
Disclosure: Dr. Pawlak has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Novartis, Roche.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
016 | A Prospective Study of Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Identifying Ultrasonographic Features for Diagnosis and Prognosis |
Disclosure: Dr. Crump has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck Serono, Teva Pharma, Biogen.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
017 | Measuring White Matter Axonal Injury in Patients with Multiple Sclerosis |
Disclosure: Dr. Chen has nothing to disclose.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
017 | Neuromuscular ultrasound for the non-invasive assessment of breast cancer patients with peripheral neuropathy from taxanes |
Disclosure: Dr. Strowd has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Innocrin Pharmaceuticals, Monteris Medical, and Novocure. Dr. Strowd has received personal compensation in an editorial capacity for Neurology. Dr. Strowd has received research support from American Society of Clinical Oncology Conquer Cancer Foundation, Southeastern Brain Tumor Foundation, and Jazz Pharmaceuticals.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
018 | Monitoring of Subclinical Disease Activity by Serum Neurofilament Light Chain Levels in Multiple Sclerosis |
Disclosure: Dr. Uher has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen Idec, Novartis, Sanofi Genzyme, Roche, and Merck. Dr. Uher has received research support from Biogen Idec, Sanofi Genzyme.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
018 | Survival prediction models in motor neuron disease |
Disclosure: Dr. Spinelli has nothing to disclose.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
019 | Myelinating Proteins in MS are Linked to Volumetric Brain MRI changes |
Disclosure: Dr. Brod has nothing to disclose.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
019 | Brain White Matter MRI Differentiates Kennedy’s Disease from Other Motor Neuron Disease Clinical Phenotypes |
Disclosure: Dr. Spinelli has nothing to disclose.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
020 | Cerebellar Structure in Patients with Parkinson’s Disease and Essential Tremor |
Disclosure: Dr. Lopez has nothing to disclose.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
021 | Regional Myelin-Specific MRI Abnormalities in Susac Syndrome Suggests Demyelination is a Pathologic Feature |
Disclosure: Dr. Johnson has nothing to disclose.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
021 | Diminished fMRI global signal differences between eyes closed and eyes open resting state in REM behavior disorder (RBD) and Parkinson’s disease |
Disclosure: Dr. Suescun has nothing to disclose.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
022 | Longitudinal Connectivity Outperforms Volumetric Change As A Marker For Prodromal Parkinson's Disease |
Disclosure: Dr. Pena has nothing to disclose.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
023 | MRI Signature of Neuromelanin and Iron Pathology in Parkinson's Disease |
Disclosure: Dr. Huddleston has nothing to disclose.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
024 | Transcranial Direct Current Stimulation (tDCS) can Enhance Physical Training Outcomes in Multiple Sclerosis (MS) |
Disclosure: Dr. Pilloni has nothing to disclose.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
024 | Structural Magnetic Resonance Imaging Correlates of Neurodegeneration in a Spinocerebellar Ataxia Type 7 Cohort |
Disclosure: Dr. Parker has nothing to disclose.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
025 | Vascular Disease Risk Factors (VDRF) in MS is Associated with Brain ATP Abnormalities: Dysmetabolism May Drive MS Disease Progression. |
Disclosure: Dr. Yadav has nothing to disclose.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
025 | Progression of Parkinson’s Disease: A Longitudinal MRI Study of Functional Brain Connectome in a Large Cohort of Patients |
Disclosure: Dr. Filippi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen Idec, Merk-Serono, Novartis, Teva Pharmaceutical Industries. Dr. Filippi has received personal compensation in an editorial capacity for Journal of Neurology. Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Teva Pharmaceutical Industries, Roche.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
026 | Cerebellar Atrophies in Neuromyelitis Optica Spectrum Disease (NMOSD) patients |
Disclosure: Dr. Souza has nothing to disclose.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
026 | Functional Network Connectivity Predicts Spreading of Cortical Atrophy in Parkinson’s Disease |
Disclosure: Dr. Agosta has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
027 | Patterns of Brain Volume Loss in Traumatic Brain Injury |
Disclosure: Dr. Meysami has nothing to disclose.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
027 | Botulinum toxin A modulates parietal cortex activity in post-stroke upper limb spasticity |
Disclosure: Dr. Hlustik has nothing to disclose.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
028 | Case Report: Sonographic demonstration of a perfusion dependent stroke with negative MRI and a flow limiting stenosis |
Disclosure: Dr. Gomez has nothing to disclose.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
029 | A Unique Case of Malignant Edema due to Cerebellar Diaschisis Necessitating Decompressive Craniectomy |
Disclosure: Dr. Hurtubise has nothing to disclose.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
029 | Early Ischemic Changes on Serial CT Imaging in Acute Ischemic Stroke |
Disclosure: Dr. Czap has nothing to disclose.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
030 | Functional Reorganization of the Language Network During Recovery from Severe Traumatic Brain Injury: A Longitudinal fMRI Study |
Disclosure: Dr. Coffey has nothing to disclose.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
030 | Focal Parietal Lobe Atrophy in Antiphospholipid Syndrome: Retrospective Analysis |
Disclosure: Dr. Wong has nothing to disclose.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
031 | Functional anomaly mapping using BOLD time-courses reveals local and distant dysfunction caused by stroke |
Disclosure: Dr. DeMarco has nothing to disclose.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
032 | Preserved Brain Functional Plasticity After Upper Limb Task-Oriented Rehabilitation in Progressive Multiple Sclerosis |
Disclosure: Dr. Boffa has nothing to disclose.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
033 | Diffusion Tensor Tractography of Brainstem Fibers and Application to Combat-Related Pain |
Disclosure: Dr. Zhang has nothing to disclose.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
033 | Novel Neuroimaging Pattern In A Patient With Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts And Leukoencephalopathy |
Disclosure: Dr. Petrea has nothing to disclose.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
034 | Babinski’s sign from the evolutional point of view "Why would you think that the big toe is related to your brain?" |
Disclosure: Dr. Elsaid has nothing to disclose.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
034 | Poor Collaterals and Malignant CT Perfusion Profiles Are Associated with Increased Vulnerability to Blood Pressure Reductions during Endovascular Therapy |
Disclosure: Dr. Strander has nothing to disclose.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
035 | Microvessel Cerebral Vasculitis and Peripheral Neuropathy as Neurologic Manifestations in Rocky Mountain Spotted Fever |
Disclosure: Dr. Danielson has nothing to disclose.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
035 | Predictors of TC-Perfusion alterations in Stroke-Mimics attended as stroke-code |
Disclosure:
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
036 | Utility of whole body 18-FDG-PET in management of Tuberculous Meningitis: A preliminary study from a tertiary care institute of North India |
Disclosure: Dr. Modi has nothing to disclose.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
036 | The first objective predictor of the hemorrhagic events after endovascular treatment of acute ischemic stroke using 2D parametric parenchymal blood flow |
Disclosure: Dr. Elsaid has nothing to disclose.
|
|
Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
037 | Timing invariant CTA derived from CTP preserves high diagnostic yield for MCA-M2 occlusions |
Disclosure: Dr. Limaye has nothing to disclose.
|